重组人血管内皮抑制素联合贝伐珠单抗治疗中晚期非小细胞肺癌的疗效及对血清CEA、CYFRA21-1和VEGF水平的影响

Efficacy of Recombinant Human Endostatin Injection Combined with Bevacizumab in the Treatment of Advanced Non-small Cell Lung Cancer and Its Effect on Serum CEA,CYFRA21-1 and VEGF Levels

目的探讨重组人血管内皮抑制素注射液联合贝伐珠单抗治疗中晚期非小细胞肺癌的疗效及对血清CEA、CYFRA21-1和VEGF水平的影响。方法选取中晚期非小细胞肺癌患者98例,随机分为2组,各49例。对照组给予贝伐珠单,治疗组在此基础上加用重组人血管内皮抑制素,对比2组用药后的临床疗效、生存情况、生活质量评分、血清CEA、CYFRA21-1和VEGF水平及不良反应发生情况。结果经过治疗后,治疗组CBR和ORR显著高于对照组(P<0.05)。2组治疗后生理状况、社交/家庭状况、情感状况、功能状况以及肺癌附加的关注评分均明显升高(P<0.05);并且治疗组升高较多(P<0.05)。治疗组OS、PFS、1年和2年生存率较对照组更高(P<0.05)。治疗后2组血清CEA、CYFRA21-1和VEGF水平显著降低(P<0.05);并且治疗组降低较明显(P<0.05)。2组在治疗过程中均出现白细胞降低、发热、胃肠道反应、皮疹及血小板下降等不良反应,且无明显差异(P>0.05)。结论贝伐珠单抗联合重组人血管内皮抑制素能够有效地治疗中晚期非小细胞肺癌,降低患者血清CEA、CYFRA21-1和VEGF水平,安全性较好,值得在临床上推广应用。

Objective To investigate the efficacy of recombinant human endostatin injection combined with bevacizumab in the treatment of advanced non-small cell lung cancer and its effect on serum CEA,CYFRA21-1 and VEGF levels.Methods A total of 98 patients with advanced non-small cell lung cancer were selected and randomly divided into 2 groups with 49 cases in each group.The control group was given bevacizumab,and the treatment group was given recombinant human endostatin on this basis.The clinical efficacy,survival status,quality of life scores,serum levels of CEA,CYFRA21-1 and VEGF and the occurrence of adverse effects of the 2 groups after treatment were compared.Results After treatment,the levels of CBR and ORR of the treatment group were significantly higher than those of the control group(P<0.05).The physiological status,social/family status,emotional status,functional status,and additional attention scores for lung cancer after treatment in the 2 groups were significantly increased(P<0.05);and the treatment group increased more(P<0.05).The OS,PFS,1-year and 2-year survival rates of the treatment group were higher than those of the control group(P<0.05).The serum levels of CEA,CYFRA21-1 and VEGF in the 2 groups were significantly reduced after treatment(P<0.05);and the reduction in the treatment group was more significant than that of the control group(P<0.05).During the treatment,the 2 groups had adverse reactions such as leukopenia,fever,gastrointestinal reactions,rash,and thrombocytopenia,and there was no significant difference between the 2 groups(P>0.05).Conclusion Bevacizumab combined with recombinant human endostatin can effectively treat middle-advanced non-small cell lung cancer and reduce the serum CEA,CYFRA21-1 and VEGF levels in patients.It is safe and worthy of clinical application.